Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial
Arthritis Care & Research · 2026
DOI: 10.1002/acr.25700 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Hermine I Brunner und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Objective
This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy.
Methods
This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier: NCT04179032) used three‐weight‐band subcutaneous dosing of belimumab 200 mg every week (qw) for pediatric patients weighing ≥50 kg, every 10 days for pediatric patients weighing 30 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
- Hospital Universitario y Politécnico La Fe, València, Spain.
- GSK, Stevenage, United Kingdom.
- Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany.
- University Hospital of Cologne, Cologne, Germany.
ORCID-Profile: Hermine I Brunner, Jordi Antón, Gerd Horneff, Andre van Maurik, Yuichi Yamasaki
Förderung
- GSK
Zitieren
APA
Brunner, H. I., Antón, J., Calvo-Penadés, I., Dimelow, R., Horneff, G., Kamphuis, S., Marino, R., van Maurik, A., Minden, K., Mori, M., Ocran-Appiah, J., Wilkinson, C., Yamasaki, Y., Assudani, D., & Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators (2026). Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial. Arthritis Care & Research. https://doi.org/10.1002/acr.25700
Vancouver
Brunner HI, Antón J, Calvo-Penadés I, Dimelow R, Horneff G, Kamphuis S, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial. Arthritis Care & Research. 2026. doi:10.1002/acr.25700
BibTeX
@article{Brunner2026,
author = {Brunner, Hermine I and Antón, Jordi and Calvo-Penadés, Inmaculada and Dimelow, Richard and Horneff, Gerd and Kamphuis, Sylvia and Marino, Rebecca and van Maurik, Andre and Minden, Kirsten and Mori, Masaaki and Ocran-Appiah, Josephine and Wilkinson, Christel and Yamasaki, Yuichi and Assudani, Deepak and Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators, Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators},
title = {Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.25700}
}
EUVIMED